Table 1.
Study characteristics, methodological design choices, surveying techniques, and quality of the included disability weights measurement studies
| Author | Year | Region or country included | Single- or Multi-cause study? | Panel of judges | Number of the panel members | Number of health states valued | Description of health states | Time Presentation | Valuation methods for health states | Surveying technique/tool | Number of tasks per panel member | CREATE score (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asadi et al. [37] | 2016 | Iran | Single (Poisonings) | ME | 10 | 50 | DS | Period Profile | Interpolation | Questionnaire | NA | 93 |
| Bae et al. [49] | 2019 | Korea | Single (Osteoporosis; osteoporotic fractures) | ME | 33 | 6 | NA | Period Profile | PTO | Face-to-face interview | 6 | 87 |
| Bakhshandeh et al. [45] | 2009 | Iran | Single (Cardiovascular diseases) | HP, PT, PX, PP | 80 | 25 | DS | NA | VAS (ranking) | Face-to-face interview | 25 | 80 |
| Baltussen et al. [50] | 2002 | Burkina Faso | Multiple | HP, PP | 56 | 9 | DS (scenario analyses) | Period Profile | Adapted VAS/ Interpolation | Group discussion & Questionnaire | 9 | 93 |
| Basiri et al. [38] | 2008 | Iran | Single (Urological disease) | ME | 10 | 76 | NA | Period Profile | Interpolation | Questionnaire | 10 | 87 |
| Brennan & Spencer [40] | 2004 | Australia | Single (Oral disease) | Model | NA | 18 | EQ-5D | Period Profile | EQ-5D: NA | NA | NA | 100 |
| Brennan et al. [39] | 2007 | Australia | Single (Peridontal disease) | Model | NA | 6 | EQ-5D | Period Profile | EQ-5D: NA | NA | NA | 100 |
| Cho et al. [46] | 2014 | Korea | Single (Multiple sclerosis) | ME | 15 | 5 | DS | Period Profile | PTO | Modified Delphi method | NA | 87 |
| Choi et al. [47] | 2013 | Korea | Single (Cancer) | ME | 32 | 24 | NA | Period Profile | VAS & PTO | NA | 24 | 87 |
| Gabbe et al. [33] | 2016 | Netherlands, United States, New Zealand, Australia, United Kingdom | Single (Injury) | Model | NA | 40 | EQ-5D | Period Profile | EQ-5D: NA | NA | NA | 100 |
| Haagsma et al. [34] | 2008 | Netherlands | Single (Injury) | PP | 143 | 44 | DS & EQ-5D | Annual profile | VAS & TTO | Panel meeting & Questionnaire | 32 | 100 |
| Haagsma et al. [51] | 2008 | Netherlands | Multiple | PP | 107 | 39 | DS & EQ-5D | Annual profile | VAS & PTO | Panel meeting & Questionnaire | 27 | 100 |
| Haagsma et al. [35] | 2009 | Netherlands | Single (Injury) | Model | NA | 7 | EQ-5D | Period Profile | EQ-5D: NA | NA | NA | 100 |
| Haagsma et al. [14] | 2015 | Hungary, Italy, Netherlands, Sweden | Multiple | PP | 30,660 | 255 | DS | Period Profile | PC & PHE | Web-based survey | 18 | 100 |
| Hong & Saver [44] | 2009 | United States, Southeast Asia | Single (Stroke) | ME | 9 | 5 | NA | NA | PTO | Panel meeting & Questionnaire | 5 | 80 |
| Havelaar et al. [41] | 2000 | Netherlands | Single Infectious disease | ME | 35 | NA | NA | Period Profile | Interpolation | Panel meeting | NA | 93 |
| Jelsma et al. [52] | 2000 | Zimbabwe | Multiple | ME, PP | 68 | 22 | NA | Period Profile | VAS & PR | Focus group discussion | NA | 80 |
| Kim et al. [53] | 2020 | Korea | Multiple | ME | 806 | 313 | DS | Period Profile | PR | Web-based survey | 20 | 93 |
| Kruijshaar et al. [54] | 2005 | Netherlands | Multiple | ME | 49 | 18 | DS & EQ-5D | Period Profile | Interpolation | Questionnaire | 18 | 100 |
| Kwong et al. [55] | 2010 | Canada | Multiple | Model | NA | NA | CLAMES | Period Profile | CLAMES: NA | NA | NA | 100 |
| Lai et al. [56] | 2009 | Estonia | Multiple | ME | 25 | 283 | DS | Period Profile | VAS & PTO | Panel meeting | NA | 93 |
| Lyons et al. [36] | 2011 | United Kingdom | Single (Injury) | Model | NA | 13 | EQ-5D | Period Profile | EQ-5D: NA | NA | NA | 93 |
| Mathers et al. [57] | 2000 | Australia | Multiple | Model | NA | NA | EQ-6D & DDW | Period Profile | EQ-6D: NA | NA | NA | 100 |
| Murray et al. [8] | 1996 | Global | Multiple | ME | 10 | 483 | DS | Period Profile | VAS & PTO | NA | NA | 87 |
| Nanjan Chandran et al. [17] | 2021 | Global | Single (Lepropsy) | PP | 667 | 3 | SF-36 HRQoL data | NA | SF-36 HRQoL data: NA (meta-analysis) | NA | NA | 100 |
| Neethling et al. [16] | 2016 | South Africa | Multiple | PP | 677 | 51 | DS (no label) | Period Profile | PC & TTO | Household face-to-face interview | 15 | 100 |
| Nontarak et al. [58] | 2020 | Thailand | Multiple | PT | 450 | 9 | DS & EQ-5D | Period Profile | VAS & EQ-5D & TTO | Face-to-face interview | NA | 87 |
| Nontarak et al. [42] | 2021 | Thailand | Single (Alcohol use disorders) | PT, PP | 300 | 3 | DS & EQ-5D | Period Profile | VAS & EQ-5D & TTO | Face-to-face interview | NA | 93 |
| Nomura et al. [13] | 2021 | Japan | Multiple | PP | 37,318 | 231 | DS (no label) | Period Profile | PC & PHE | Web-based survey | 18 | 100 |
| Ock et al. [59] | 2016 | Korea | Multiple | HP | 496 | 228 | DS | Period Profile | PC & PTO | Web-based survey | 60 | 93 |
| Ock et al. [15] | 2016 | Korea | Multiple | PP | 5916 | 256 | DS | Period Profile | PC & VAS & SG & PHE | Household survey & Web-based survey | 22 | 93 |
| Ock et al. [60] | 2019 | Korea | Multiple | HP | 605 | 289 | DS (no label) | Period Profile | PR | Web-based survey | 20 | 93 |
| Park & Jung [61] | 2017 | Korea | Multiple | Model | NA | 243 | EQ-5D | NA | EQ-5D: NA | NA | 100 | |
| Piao et al. [62] | 2021 | Japan | Multiple | HP | 286 | 17 | DS | Period Profile | PC & PHE | Questionnaire | NA | 87 |
| Poenaru et al. [18] | 2017 | Kenya, Canada | Single (Paediatric conditions) | HP | 154 | 15 | DS & EQ-5D | NA | PR & VAS & PC & TTO | Focus groups | NA | 87 |
| Rehm & Frick [63] | 2013 | United States | Multiple | ME | 68 | 12 | DS + CLAMES | NA | PC & PR & PTO | NA | NA | 87 |
| Salomon et al. [12] | 2012 | Global | Multiple | PP | 30,230 | 220 | DS (no label) | Period Profile | PC & PHE | Household survey; Web-based survey | 18 | 100 |
| Salomon et al. [20] | 2015 | Global | Multiple | PP | 30,230 & 30,660 | 235 | DS (no label) | Period Profile | PC | Web-based survey (GBD 2010; European surveys; Household surveys; USA surveys) | 18 | 100 |
| Sanderson et al. [43] | 2001 | Australia | Sinlge (Mental disorders) | ME | 20 | 19 | DS | NA | PTO & Rating scale & PR | Panel meeting | 19 | 87 |
| Schwarzinger et al. [64] | 2003 | Europe | Multiple | ME, nHP | 232 | 15 | DS & EQ-5D | Period Profile | VAS & PTO & TTO | Panel meeting | 15 | 93 |
| Steckling et al. [19] | 2017 | Global | Multiple | ME | 18 | 105 | DS & EQ-5D | Period Profile | VAS & PC/ Interpolation | Web-based survey | NA | 87 |
| Stouthard et al. [65] | 1997 | Netherlands | Multiple | ME | 38 | 175 | DS & EQ-5D | Period Profile & Annual Profile | VAS & PTO | Panel meeting & Questionnaire | 47 | 93 |
| Ustün et al. [66] | 1999 | Global | Multiple | HP, PT, PX, PM | 241 | 17 | DS | Period Profile | PR | Interview | 17 | 93 |
| Van Spijker et al. [67] | 2011 | Netherlands | Multiple | ME | 16 | 12 | DS & EQ-5D | Period Profile | VAS | Questionnaire | 12 | 100 |
| Yoon et al. [48] | 2000 | Korea | Single (Cancer) | ME | 19 | 12 | NA | NA | PTO & Interpolation | Delphi method | NA | 80 |
| Yoon et al. [68] | 2007 | Korea | Multiple | ME | 30 | 123 | NA | Period Profile | PTO & Interpolation | Panel meeting | 53 | 93 |
NA Not Available, DDW Dutch Disability Weight
Panel of judges
ME Medical experts, HP Health professionals, nHP Non-health professionals, PT Patients or people with disabilities, PX Patient proxies, PM Policy-makers, PP Population
Description of health states
DS Disease-specific health state description, EQ-5D European Quality of Life instrument that consists of five dimensions/attributes (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), EQ-6D EQ-5D appended with a cognitive dimension/attribute, CLAMES Classification and Measurement System of Functional Health, SF-36 HRQoL Short form health-related quality of life survey
Valuation methods for health states
VAS Visual analog scale, TTO Time trade-off PTO Person trade-off, PC Paired comparison, PHE Population health equivalence, PR Preference ranking, SG Standard gamble
CREATE
CREATE: Checklist for Reporting Valuation Studies instrument